MaxCyte stock slips 4.03 percent as new chief arrives

MaxCyte stock slipped 4.03 percent to USD 1.19 in Nasdaq trading on September 23, 2026, putting the biotechnology company at a market value of USD 127,474,790. The move followed the appointment of Sidharth Kapileshwar as chief corporate development officer, announced on September 23, 2026. The leadership change adds a corporate development specialist as MaxCyte works to broaden its cell engineering platform partnerships.

Revenue fell to USD 7.3 million

MaxCyte reported Q2 2026 revenue of USD 7.3 million, down 15 percent from USD 8.5 million in the comparable quarter, according to The Globe and Mail. The company also posted a net loss of USD 8.9 million for the quarter, compared with USD 12.4 million a year earlier.

Core revenue declined 21 percent to USD 6.5 million, while operating expenses fell 25 percent to USD 15.8 million, the transcript said. That combination shows the current tension in MaxCyte's model: cost reductions are cushioning weaker licensing and instrument revenue, but the top line remains dependent on partner activity and customer purchasing schedules.

Guidance stays at USD 30 million

Management retained 2026 total revenue guidance of USD 30 million to USD 32 million, including USD 25 million to USD 27 million of core revenue and USD 5 million from strategic platform license milestones and royalties, according to The Globe and Mail. Management expects low single-digit year-over-year growth in the second half and gross margin in the mid-70s.

The Genentech enterprise partnership is designed to support multiple cell therapy programs across research, clinical development and manufacturing. That structure could diversify revenue beyond single-program licenses, although the Q2 figures show that the transition has not yet offset the decline from discontinued partner programs.

New executive joins the strategy team

Investing.com reported on September 23, 2026, that Kapileshwar joined MaxCyte from Danaher, where he served as vice president of innovation for the Life Sciences Platform. A separate company announcement said he brings experience in corporate development, strategy, innovation and mergers and acquisitions across life sciences and technology companies.

MaxCyte stock stood at USD 1.19 on Nasdaq on September 23, 2026, with a 52-week range of USD 0.64 to USD 1.86. The 4.03 percent daily decline leaves the shares 36.02 percent below the 52-week high, while the company's second-quarter revenue and retained guidance give investors two contrasting measures of the turnaround effort.